Tempest Therapeutics Stockholders Extend Rights Plan and Approvals

Tempest Therapeutics ( (TPST) ) just unveiled an announcement.

On January 27, 2026, stockholders of Tempest Therapeutics approved an extension of the company’s limited-duration stockholder rights plan, keeping it in place through October 10, 2026, in a move that helps preserve the existing shareholder base and guard against potential hostile takeovers. At the same 2025 Annual Meeting of Stockholders, investors also ratified an amendment to the 2023 Equity Incentive Plan to add 1,410,000 shares for equity awards, elected Geoff Nichol as a Class I director through the 2028 annual meeting, endorsed executive compensation on an advisory basis, confirmed Ernst & Young LLP as auditor for 2025, and authorized the issuance of 8,268,495 shares of common stock to satisfy obligations under a November 19, 2025 asset purchase agreement with Erigen LLC and Factor Bioscience, collectively signaling support for the company’s current governance, compensation, financing, and acquisition strategies.

The most recent analyst rating on (TPST) stock is a Sell with a $3.00 price target. To see the full list of analyst forecasts on Tempest Therapeutics stock, see the TPST Stock Forecast page.

Spark’s Take on TPST Stock

According to Spark, TipRanks’ AI Analyst, TPST is a Neutral.

The score is primarily constrained by weak financial performance (no revenue, sizable losses, heavy cash burn, and a reduced equity cushion). Technicals also weigh heavily due to a clear downtrend across all major moving averages and negative MACD. Valuation provides limited support given the negative P/E and no dividend, while the Nasdaq noncompliance notice adds an additional risk factor.

To see Spark’s full report on TPST stock, click here.

More about Tempest Therapeutics

Average Trading Volume: 127,847

Technical Sentiment Signal: Sell

Current Market Cap: $14.29M

See more data about TPST stock on TipRanks’ Stock Analysis page.